Andere talen Neuronetics, Inc.

Aandelen

STIM

US64131A1051

Geavanceerde medische apparatuur & technologie

Beurs gesloten - Nasdaq Andere beurzen 22:00:00 11-12-2024			Variatie 5 dagen	Verschil t.o.v. 1 jan (%)
1,200 ^USD	+5,26%		+2,13%	-58,62%

12/11	Neuronetics, Inc., Q3 2024 Earnings Call, Nov 12, 2024
12/11	Neuronetics, Inc. rapporteert resultaten voor het derde kwartaal en de negen maanden eindigend op 30 september 2024	CI

Andere talen

Krijg toegang tot al het nieuws over alle bedrijven: mis nooit meer een winstgevende beleggingskans!

Gratis inschrijven

Neuronetics : and Greenbrook TMS Announce Closing of Transaction Form 8 K	10/12
Neuronetics and Greenbrook TMS Announce Closing of Transaction	10/12
Neuronetics, Inc. completed the acquisition of Greenbrook TMS Inc. (OTCPK:GBNH.F) from Madryn Health Partners II (Cayman Feeder), LP, fund managed by Madryn Asset Management, LP, 1315 Capital II, L.P. fund managed by 1315 Capital, LLC, Greybrook Health Inc. and others for $0.58 million.	09/12
Neuronetics to Present at the Piper Sandler 36th Annual Healthcare Conference	20/11
Neuronetics Reports Inducement Grant under Nasdaq Listing Rule 5635(4)	13/11
Neuronetics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)	12/11
Neuronetics : Proxy Results Form 8 K	12/11
Neuronetics : Reorganization Form 8 K	12/11
Neuronetics : Reports Record Third Quarter 2024 Financial and Operating Results Form 8 K	12/11
Earnings Flash (STIM) NEURONETICS Reports Q3 Revenue $18.5M	12/11
Neuronetics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2024	12/11
Neuronetics: Q3 Earnings Snapshot	12/11
Neuronetics Reports Record Third Quarter 2024 Financial and Operating Results	12/11
Neuronetics, Inc. Provides Standalone Earnings Guidance for the Fourth Quarter and Full Year 2024	12/11
Neuronetics to Report Third Quarter 2024 Financial and Operating Results and Host Conference Call	29/10
NeuroStar® Oral Presentation at AACAP 2024 Highlights Largest Study Evaluating TMS Efficacy in Adolescents with Depression	14/10
NeuroStar® Oral Presentation at AACAP 2024 Highlights Largest Study Evaluating TMS Efficacy in Adolescents with Depression	14/10
Neuronetics, Greenbrook Receive Interim Order for Special Meeting of Shareholders for Greenbrook	04/10
Neuronetics : and Greenbrook TMS Announce Receipt of Interim Order in Respect of Proposed Arrangement and Provide Details of Shareholder Meetings Form 8 K	04/10
Neuronetics and Greenbrook TMS Announce Receipt of Interim Order in Respect of Proposed Arrangement and Provide Details of Shareholder Meetings	04/10
Health Care Service Corporation Adds First-Line TMS Coverage for Adolescents	25/09
Expanded Health Policies Enhance TMS Therapy Access for Adolescents and Adults	19/09
Expanded Health Policies Enhance TMS Therapy Access for Adolescents and Adults	19/09
Neuronetics, Inc. Expands Health Policies Enhance Tms Therapy Access for Adolescents and Adults	19/09
NeuroStar® Releases Software Upgrades to Elevate Patient Care	16/09

Geen resultaten voor deze zoekopdracht

Al het nieuws Aanbevelingen van analisten Belangrijkste gebeurtenissen Insiders Transcripties Persberichten Officiële publicaties Andere talen Ideeën voor de handel MarketScreener-artikels MarketScreener-analyses

Andere talen Neuronetics, Inc.

Aandelen

STIM

US64131A1051

Geavanceerde medische apparatuur & technologie

Andere talen

Filters